UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Annals of oncology, 2011-05, Vol.22 (5), p.1078-1087

2011

Volltextzugriff (PDF)

OC-021: Biomarker results from BERIL-1: buparlisib and paclitaxel in patients with platinum-pretreated SCCHN

Radiotherapy and oncology, 2017-03, Vol.122, p.14-14

2017

Volltextzugriff (PDF)

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study

Annals of oncology, 2017-09, Vol.28 (9), p.2213-2218

2017

Volltextzugriff (PDF)

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial

British journal of cancer, 2013-09, Vol.109 (5), p.1117-1122

2013

Volltextzugriff (PDF)

Molecular identification, expression and prognostic role of estrogen- and progesterone receptors in head and neck cancer

International journal of oncology, 2007-01, Vol.30 (1), p.155-160

2007

Volltextzugriff (PDF)

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Annals of oncology, 2014-03, Vol.25 (3), p.682-688

2014

Volltextzugriff (PDF)

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial

Annals of oncology, 2017-09, Vol.28 (9), p.2219-2224

2017

Volltextzugriff (PDF)

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971 TAX 323)

British journal of cancer, 2010-10, Vol.103 (8), p.1173-1181

2010

Volltextzugriff (PDF)

8533 POSTER First Results of an Uncontrolled, Phase II Trial of Induction Chemotherapy With Cetuximab and Docetaxel-Cisplatin-5FU Followed by Cetuximab+Radiotherapy in the Responders in Locally Advanced Resectable Squamous Cell Cancer of the Head and Neck

European journal of cancer (1990), 2011, Vol.47, p.S553-S553

2011

Volltextzugriff (PDF)

The Effect of Leukocyte Interleukin Injection (Multikine®) Treatment on the Peritumoral and Intratumoral Subpopulation of Mononuclear Cells and on Tumor Epithelia: A Possible New Approach to Augmenting Sensitivity to Radiation Therapy and Chemotherapy in Oral Cancer-A Multicenter Phase I/II Clinical Trial

The Laryngoscope, 2003-12, Vol.113 (12), p.2206-2217

2003

Volltextzugriff (PDF)

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease

European journal of cancer (1990), 2013-05, Vol.49 (7), p.1609-1618

2013

Volltextzugriff (PDF)

Progression of head and neck squamous cell cancer

Cancer and metastasis reviews, 2005-01, Vol.24 (1), p.107-127

2005

Volltextzugriff (PDF)

Should chemotherapy alone be the initial treatment for glottic squamous cell carcinoma?: Arbiter

European journal of cancer (1990), 1999, Vol.35 (9), p.1312-1313

1999

Volltextzugriff (PDF)

Malignant mucosal melanoma of the head and neck

Pathology oncology research, 2003, Vol.9 (1), p.7-12

2003

Volltextzugriff (PDF)

Mutagen sensitivity of patients with cancer at different sites of the head and neck

Mutagenesis, 2005-09, Vol.20 (5), p.381-385

2005

Volltextzugriff (PDF)

Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.5508-5508

2004

Volltextzugriff (PDF)

Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.5508-5508

2004

Volltextzugriff (PDF)

Molecular identification, expression and prognostic role of estrogen alpha, beta and progesteron receptors in head and neck cancer

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.20056-20056

2006

Volltextzugriff (PDF)

Does the bleomycin sensitivity assay express cancer phenotype?

Mutagenesis, 2003-01, Vol.18 (1), p.59-63

2003

Volltextzugriff (PDF)

Should chemotherapy alone be the initial treatment for glottic squamous cell carcinoma?

European journal of cancer (1990), 1999-09, Vol.35 (9), p.1312-1313

1999

Volltextzugriff (PDF)

5548 POSTER Circulating hormone levels and prognosis in head and neck cancer

European journal of cancer supplements, 2007, Vol.5 (4), p.338-338

2007

Volltextzugriff (PDF)

Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer

Radiotherapy and oncology, 2003-08, Vol.68 (2), p.171-174

2003

Volltextzugriff (PDF)

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase 1/11 ADVANTAGE trial (phase II part)

Annals of oncology, 2014, Vol.25 (3), p.682-688

2014

Volltextzugriff (PDF)

Prognostic impact of the steroid receptor level in head and neck cancer

European journal of cancer (1990), 1999-09, Vol.35, p.S173-S173

1999

Volltextzugriff (PDF)

Long-term results from EORTC24971/TAX323: Comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5530-5530

2011

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(75)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(38)
Science & Technology
(32)
Life Sciences & Biomedicine
(27)
Male
(27)
Female
(24)
Adult
(22)
Middle Aged
(21)
Aged
(19)
Oncology
(19)
Biological And Medical Sciences
(12)
Medical Sciences
(10)
Head And Neck Neoplasms - Pathology
(9)
Treatment Outcome
(9)
Tumors
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Carcinoma, Squamous Cell - Pathology
(8)
Head And Neck Cancer
(8)
Head And Neck Neoplasms - Drug Therapy
(8)
Otorhinolaryngology. Stomatology
(8)
Carcinoma, Squamous Cell - Drug Therapy
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

OC-021: Biomarker results from BERIL-1: buparlisib and paclitaxel in patients with platinum-pretreated SCCHN

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial

Molecular identification, expression and prognostic role of estrogen- and progesterone receptors in head and neck cancer

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971 TAX 323)

8533 POSTER First Results of an Uncontrolled, Phase II Trial of Induction Chemotherapy With Cetuximab and Docetaxel-Cisplatin-5FU Followed by Cetuximab+Radiotherapy in the Responders in Locally Advanced Resectable Squamous Cell Cancer of the Head and Neck

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease

Progression of head and neck squamous cell cancer

Should chemotherapy alone be the initial treatment for glottic squamous cell carcinoma?: Arbiter

Malignant mucosal melanoma of the head and neck

Mutagen sensitivity of patients with cancer at different sites of the head and neck

Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971)

Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971)

Molecular identification, expression and prognostic role of estrogen alpha, beta and progesteron receptors in head and neck cancer

Does the bleomycin sensitivity assay express cancer phenotype?

Should chemotherapy alone be the initial treatment for glottic squamous cell carcinoma?

5548 POSTER Circulating hormone levels and prognosis in head and neck cancer

Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase 1/11 ADVANTAGE trial (phase II part)

Prognostic impact of the steroid receptor level in head and neck cancer

Long-term results from EORTC24971/TAX323: Comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN)

Suchergebnisse filtern